| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447710 | European Journal of Cancer | 2011 | 7 Pages |
Abstract
The ERSPC risk calculator discriminated well between those with and without prostate cancer among initially screened men, but overestimated the risk of a positive biopsy. Further research is necessary to assess the performance and applicability of the ERSPC risk calculator when a clinical setting is considered rather than a screening setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Heidi A. van Vugt, Monique J. Roobol, Ries Kranse, Liisa Määttänen, Patrik Finne, Jonas Hugosson, Chris H. Bangma, Fritz H. Schröder, Ewout W. Steyerberg,